KRAS and metastatic colorectal cancer: Grasselli et al [43] also investigated the performance of BEAMing in detecting KRAS mutation in plasma and tissue of metastatic colorectal cancer and results showed sensitivity of 85.7%, specificity of 94%, and concordance rate of 89.7%.